After the Withdrawal Is Over — Your Brain Is Still Healing: Understanding Post-Acute Withdrawal Syndrome from Opioids
A comprehensive guide to PAWS, the two-phase symptom timeline, and evidence-based treatments from an integrative psychiatrist in Palm Beach, Florida
Most people believe the hardest part of quitting opioids is getting through the acute withdrawal — the sweating, vomiting, restless legs, and physical agony of the first week. And while that week is undeniably brutal, many patients are blindsided by what comes next: a prolonged, often months-long period of psychological and neurological dysfunction that can feel just as destabilizing as the detox itself.
This is called Post-Acute Withdrawal Syndrome, or PAWS — and it is one of the most underrecognized reasons people relapse even after successfully completing detoxification.
At my integrative psychiatry practice in Palm Beach, Florida, I work with young adults and adults across the state navigating early opioid recovery. Understanding PAWS — what it is, why it happens, and how to treat it — is central to achieving durable sobriety.
What Is PAWS, and Which Opioids Cause It?
Post-Acute Withdrawal Syndrome refers to a constellation of neurological, emotional, and cognitive symptoms that persist well beyond the acute detoxification period. These symptoms arise because opioids fundamentally restructure the brain’s reward, stress, and regulatory systems — and the brain requires weeks to months to recover its natural baseline function.
PAWS can occur after cessation of any opioid, including:
- Prescription opioids: oxycodone (OxyContin, Percocet), hydrocodone (Vicodin, Norco), oxymorphone (Opana), morphine, hydromorphone (Dilaudid)
- Illicit opioids: fentanyl and fentanyl analogs (now the dominant driver of overdose deaths), heroin
- Natural and semi-synthetic opioids: kratom (mitragynine and 7-hydroxymitragynine, which act on mu-opioid receptors), codeine
- Over-the-counter combinations: products containing doxylamine or antihistamines sometimes used to potentiate opioids, complicating the withdrawal picture
Fentanyl deserves special mention. Because of its extreme potency and lipophilicity — meaning it penetrates and redistributes throughout fatty brain tissue — fentanyl withdrawal and subsequent PAWS can be particularly severe and prolonged. Patients who were using fentanyl, even unknowingly (as fentanyl is now found in counterfeit pills and other substances), often experience a more intense and protracted PAWS course.
Kratom, increasingly common among young adults, is frequently dismissed as “just an herbal supplement,” but chronic daily kratom use produces genuine opioid receptor dependence. Kratom PAWS mirrors that of traditional opioids and can be equally debilitating.
Why does PAWS happen? Opioids flood the brain’s mu-opioid receptors with artificial stimulation, causing the brain to dramatically downregulate its natural opioid system (endorphins), dopamine production, and stress-regulation circuitry. When the drug is removed, these systems don’t snap back overnight — they must slowly regenerate. PAWS is the symptomatic expression of that regeneration process.
The PAWS Timeline: Two Distinct Phases
While individual experiences vary considerably based on opioid type, duration of use, dose, and individual neurobiology, PAWS tends to unfold in two recognizable phases.
🗓 Month 1: The Emotional Withdrawal
- Depression — pervasive low mood, hopelessness, tearfulness; dopamine and serotonin systems are depleted
- Anxiety — persistent generalized anxiety, sometimes with panic attacks; the stress-hormone axis is dysregulated
- Intense cravings — drug-seeking urges that are neurologically driven, not simply “weakness”
- Insomnia — profound difficulty falling and staying asleep; the brain’s sleep architecture has been disrupted
- Physical fatigue — overwhelming tiredness, low energy even without exertion
- Irritability and dysphoria — a gray, restless emotional state distinct from sadness
🗓 Month 2 and Beyond: The Neurological Plateau
- Anhedonia — the inability to feel pleasure, interest, or joy from activities that once brought satisfaction; the hallmark of dopaminergic depletion
- Mood instability and emotional blunting — emotions feel either numbed and flat, or swing unpredictably
- Cognitive slowing and brain fog — difficulty thinking quickly, processing information, or holding a train of thought
- Cognitive dulling — reduced sharpness, mental clarity, and creative thinking
- Boredom and apathy — an inability to feel motivated or engaged; life feels colorless
- Compulsive thinking patterns — intrusive, repetitive thoughts about using; can resemble OCD
- Ongoing insomnia — sleep disturbances frequently persist into the second and third months
It is important to understand that these symptoms are not character flaws, lack of willpower, or signs that the patient “didn’t really want to get sober.” They are the predictable neurobiological consequences of prolonged opioid exposure — and they are treatable.
Composite Case Study: What PAWS Can Look Like
COMPOSITE PATIENT — “RYAN” (FICTIONAL, FOR ILLUSTRATION)
Ryan is a 26-year-old from West Palm Beach who had been using oxycodone prescribed after a sports injury, which gradually escalated to purchasing counterfeit “M30” pills that turned out to contain fentanyl. After a medically supervised detox at a facility in South Florida, his physical symptoms resolved within about a week. But by week three, Ryan was devastated: he couldn’t sleep more than two to three hours a night, he felt a crushing gray heaviness in his chest every morning, and the activities he used to love — fishing, playing guitar, spending time with his girlfriend — felt completely empty to him. He described it as “being a robot.” By weeks six through eight, his sleep had marginally improved, but he was struggling with what he called “mental molasses” — he couldn’t concentrate at work, he forgot what he’d just read, and he felt compelled by repetitive thoughts about using that terrified him.
When Ryan came to my practice, we recognized this immediately as classic opioid PAWS. With a structured treatment plan combining individual therapy, targeted pharmacotherapy, and lifestyle interventions, Ryan began showing meaningful improvement by month three and reported feeling “like himself again” by month five.
Psychiatric Symptoms That Arise During PAWS
Beyond the core PAWS features, several distinct psychiatric syndromes can emerge or become prominent during post-acute withdrawal that require targeted clinical attention:
Major Depressive Episodes
A substantial proportion of opioid-dependent individuals had pre-existing depression that was being self-medicated. PAWS unmasks and often intensifies these vulnerabilities. The depleted dopamine and serotonin state of early recovery is neurobiologically identical in many ways to major depression — because in a functional sense, it is.
Panic Disorder
Heightened sensitivity of the noradrenergic system during PAWS predisposes patients to spontaneous panic attacks — sudden, overwhelming episodes of heart racing, shortness of breath, chest tightness, derealization, and fear of dying. These episodes can be profoundly destabilizing and, if untreated, lead to avoidance behaviors and relapse.
Obsessive-Compulsive Patterns
Many patients in PAWS describe intrusive, repetitive, ego-dystonic thoughts about using — thoughts they do not want but cannot suppress. These patterns engage the same cortico-striato-thalamic circuits implicated in OCD. They are not the same as craving, per se, but they increase distress and relapse risk substantially.
Brain Fog and Cognitive Impairment
Fatigue, drowsiness, poor concentration, slow information processing, and memory lapses are among the most functionally impairing aspects of PAWS — particularly for young adults trying to return to school or work. They reflect hypofrontality (reduced prefrontal cortex activity) and disruption of dopaminergic circuits critical for working memory and executive function.
Treatment Approaches: Therapy
No medication can fully substitute for structured psychological treatment during PAWS. The most effective recovery programs integrate both therapeutic and pharmacological approaches.
Individual Therapy
One-on-one therapy provides the private space to process the complex shame, grief, trauma, and identity disruption that accompany opioid use disorder. Cognitive-Behavioral Therapy (CBT) is the most evidence-based modality for relapse prevention, teaching patients to identify cognitive distortions that drive craving cycles, restructure catastrophic thinking, and develop behavioral coping strategies. Motivational Enhancement Therapy (MET) can be particularly valuable early in recovery to strengthen internal motivation during the low-dopamine, anhedonic phase when everything feels pointless. Trauma-focused approaches (EMDR, somatic therapies) are frequently necessary, as unresolved trauma is one of the most powerful drivers of opioid use disorder.
Group Therapy
Group therapy addresses the profound social isolation and shame that pervades opioid use disorder and PAWS. Hearing that others share the same terrifying thought patterns, the same anhedonia, and the same brain fog normalizes the experience and reduces the hopelessness that drives relapse. Evidence-based group formats include Seeking Safety, Cognitive Processing Therapy groups, and standard process groups led by a licensed clinician. Support groups like NA and SMART Recovery provide important peer community but are not a clinical substitute for professional group therapy.
Treatment Approaches: Pharmacotherapy
Several medications have meaningful roles in managing the specific symptoms of PAWS. Careful selection, dosing, and sequencing are essential — and should always occur under the supervision of a psychiatrist familiar with addiction medicine.
| Medication | Target Symptoms in PAWS | Clinical Considerations |
|---|---|---|
| Clonidine\n\n(alpha-2 agonist) | Anxiety, panic attacks, hyperarousal, autonomic dysregulation, insomnia (sleep onset), cravings | Suppresses noradrenergic hyperactivity — the biological driver of anxiety and panic in PAWS. Can be used scheduled or PRN for panic. Monitor blood pressure. Often used in the first 4–8 weeks of PAWS. |
| Buprenorphine / Suboxone\n\n(partial mu-agonist + naloxone) | Cravings, anhedonia (partial), depression, dysphoria, obsessive drug thoughts | The gold-standard pharmacotherapy for opioid use disorder. Reduces craving-driven obsessive thinking and partially restores opioid tone that supports mood and motivation. Should be considered the foundation of OUD treatment during PAWS in most patients. REMS enrollment required in Florida. |
| Naltrexone\n\n(opioid antagonist) | Cravings, relapse prevention, compulsive opioid-seeking thoughts | Blocks opioid receptors completely. Available as oral daily dosing or monthly injectable (Vivitrol). Appropriate for highly motivated patients who have completed detox and are opioid-free; contraindicated with ongoing opioid use. Less effective for anhedonia and may transiently worsen mood in some patients early on. |
| Trazodone\n\n(SARI antidepressant) | Insomnia, depression, anxiety | Excellent first-line agent for PAWS-related insomnia. Low-dose trazodone (50–150 mg HS) improves sleep architecture without creating dependence. Higher doses contribute antidepressant effect. Non-addictive and well-tolerated. |
| Quetiapine (Seroquel)\n\n(atypical antipsychotic) | Insomnia, anxiety, mood instability, emotional lability | Low-dose quetiapine (25–100 mg HS) is widely used for PAWS-associated insomnia and mood dysregulation. Provides sedation, anxiolysis, and mood stabilization. Used off-label; watch for metabolic side effects and orthostasis. Not appropriate as a first-line agent but highly useful in complex cases. |
| Escitalopram (Lexapro)\n\n(SSRI) | Depression, anxiety, panic disorder, OCD-spectrum intrusive thoughts, generalized anxiety | A clean, well-tolerated SSRI. Particularly useful for PAWS patients with comorbid anxiety disorders, panic attacks, or obsessive-compulsive craving patterns. Takes 4–6 weeks to reach full effect; counsel patients carefully about this delay. Watch for early activation/anxiety in the first 1–2 weeks. |
| Venlafaxine XR (Effexor)\n\n(SNRI) | Depression, anxiety, panic disorder, pain (common PAWS comorbidity), cognitive symptoms | The norepinephrine component may provide additional benefit for cognitive sluggishness and fatigue compared to SSRIs alone. Strong evidence base for panic disorder. Important caveat: venlafaxine has its own discontinuation syndrome and must be tapered carefully. A thoughtful choice for PAWS patients with prominent pain, cognitive blunting, or SSRI non-response. |
| Modafinil (Provigil)\n\n(wakefulness-promoting agent) | Brain fog, fatigue, cognitive slowing, drowsiness, anhedonia (adjunct) | One of the most clinically valuable agents for the cognitive symptoms of PAWS. Modafinil promotes wakefulness and prefrontal dopaminergic activity without the abuse potential of stimulants. Particularly useful for patients struggling to function at work or school due to mental fog and cognitive dulling. Some evidence also for reducing craving in stimulant co-use disorders. Schedule IV in the US — thoughtful patient selection required. |
A note on benzodiazepines: These drugs are frequently requested by patients in PAWS for anxiety and insomnia — and should generally be avoided. Benzodiazepines carry a high risk of misuse in this population, produce tolerance rapidly, and worsen cognitive impairment. Non-addictive alternatives like clonidine, hydroxyzine, trazodone, and low-dose quetiapine are far safer choices in the context of opioid use disorder.
An Integrative Approach to PAWS
Medication and therapy alone do not address the full biological landscape of PAWS recovery. An integrative psychiatry approach incorporates evidence-based lifestyle interventions that directly accelerate neurological healing:
Exercise is perhaps the most powerful non-pharmacological intervention for PAWS. Regular aerobic exercise upregulates BDNF (brain-derived neurotrophic factor), promotes dopamine receptor recovery, improves sleep architecture, reduces anxiety, and directly counteracts anhedonia. I recommend patients begin with 30 minutes of moderate cardio at least five days per week as a therapeutic intervention — not optional self-care.
Sleep hygiene and regulation are essential because chronic opioid use devastates the normal sleep cycle. Sleep is when the brain consolidates learning, clears metabolic waste, and restores emotional regulation. Rigid sleep schedules, avoidance of screens after dark, and targeted pharmacotherapy for insomnia are all components of PAWS recovery.
Nutritional psychiatry supports neurological repair during PAWS. Omega-3 fatty acids (EPA and DHA), magnesium glycinate, vitamin D, and B-complex vitamins all support neurotransmitter production and nervous system healing. Many patients in early recovery are nutritionally depleted and benefit meaningfully from a structured supplementation protocol.
Mindfulness-based approaches — including MBSR (Mindfulness-Based Stress Reduction) and mindfulness-based relapse prevention (MBRP) — have strong evidence for reducing craving reactivity and improving emotional regulation during PAWS. They directly address the hyperactivated stress-response system.
What to Tell Your Patients (and Yourself) About PAWS
One of the most therapeutically powerful interventions in PAWS is psychoeducation. When patients understand that their depression is not evidence that they will never feel normal again, but rather a predictable phase of neurological healing with a well-documented trajectory, it reframes their experience profoundly. The anhedonia is not permanent. The brain fog lifts. The panic attacks become manageable. But it requires time, support, and a comprehensive treatment plan.
For most patients, meaningful neurological recovery from opioid PAWS occurs over three to twelve months. With appropriate pharmacotherapy and therapeutic support, many patients feel substantially better by months three to four. Understanding this timeline — and having clinical support throughout it — is what separates successful long-term recovery from relapse.
Struggling With PAWS After Opioid Cessation?
Dr. Mark Agresti is a board-certified integrative psychiatrist in Palm Beach, Florida, specializing in substance use disorders, mood disorders, and the comprehensive treatment of Post-Acute Withdrawal Syndrome. He provides concierge in-person care in Palm Beach and statewide telemedicine throughout Florida.